Andrea Lobo

Porto

Scientific Writer at Freelance

Articles

Level of physical activity tied to less pain in SCD: Senegal Study

2 days ago | sicklecellanemianews.com | Andrea Lobo

Most people with sickle cell disease (SCD) seem to meet or exceed current physical activity recommendations for the general population, a recent study in Senegal shows. Notably, greater step counts and time spent in more intense activities were associated with lower pain frequency and intensity, as well as lower blood viscosity, which refers to higher blood thickness due to the clumping of red blood cells.
Navenibart continues to reduce HAE attacks in long-term trial

2 days ago | angioedemanews.com | Andrea Lobo

Navenibart, an experimental treatment from Astria Therapeutics to prevent swelling episodes in people with hereditary angioedema (HAE), continues to show strong and sustained benefits in a long-term clinical trial. New data from the ALPHA-SOLAR Phase 2 (NCT06007677) open-label extension study show treatment with navenibart every three to six months reduced the monthly rate of HAE attacks by a mean of 92% over 10.1 months of follow-up.
Switching from Soliris to Ultomiris safe, effective for aHUS: Study

3 days ago | ahusnews.com | Andrea Lobo

Switching from Soliris (eculizumab) to Ultomiris (ravulizumab) is a safe and effective treatment strategy for people with atypical hemolytic uremic syndrome (aHUS), according to a real-world study in Japan. The treatment switch was associated with stable levels of blood and kidney-related disease markers, preventing disease relapse or worsening and the need for additional treatment for most patients after one year, data showed.
Switching from Soliris to Ultomiris safe, effective for aHUS: Study

3 days ago | buff.ly | Andrea Lobo

Switching from Soliris (eculizumab) to Ultomiris (ravulizumab) is a safe and effective treatment strategy for people with atypical hemolytic uremic syndrome (aHUS), according to a real-world study in Japan. The treatment switch was associated with stable levels of blood and kidney-related disease markers, preventing disease relapse or worsening and the need for additional treatment for most patients after one year, data showed.
Rare dual diagnosis of lupus and PCT detailed in case report

3 days ago | porphyrianews.com | Andrea Lobo

A recent case report describes a rare instance of a woman diagnosed with both porphyria cutanea tarda (PCT) and systemic lupus erythematosus (SLE), an autoimmune disease. Her diagnosis was confirmed through laboratory tests and tissue biopsies. “The diagnosis of both pathologies becomes a challenge for physicians in diagnosis and treatment, as shown in this case, since porphyria can be the first and only manifestation of underlying systemic lupus erythematosus,” researchers wrote.
Rare dual diagnosis of lupus and PCT detailed in case report

3 days ago | buff.ly | Andrea Lobo

A recent case report describes a rare instance of a woman diagnosed with both porphyria cutanea tarda (PCT) and systemic lupus erythematosus (SLE), an autoimmune disease. Her diagnosis was confirmed through laboratory tests and tissue biopsies. “The diagnosis of both pathologies becomes a challenge for physicians in diagnosis and treatment, as shown in this case, since porphyria can be the first and only manifestation of underlying systemic lupus erythematosus,” researchers wrote.
Link between RAB32 mutation, Parkinson's focus of research grant

3 days ago | parkinsonsnewstoday.com | Andrea Lobo

A three-year grant from Parkinson Canada will allow a Canadian researcher to investigate the mechanisms by which a recently found mutation in the RAB32 gene is linked to Parkinson’s disease. The $135,000 grant will allow Jay Penney, PhD, associate professor at the University of Prince Edward Island in Canada, to understand how the RAB32 mutation affects the function of neurons and microglia, the resident immune cells in the brain, and increases the risk for Parkinson’s.
Aspiration events tied to higher risk of respiratory complications

3 days ago | rettsyndromenews.com | Andrea Lobo

An aspiration event— when something other than air enters the lungs — increases the risk of lower respiratory tract infection and respiratory failure in people with Rett syndrome, a study found. Patients with known or suspected aspiration events more commonly had risk factors like epilepsy and difficulty swallowing, and were more likely to be hospitalized.
NLRP3 inhibitor found safe, well tolerated in Parkinson’s trial

5 days ago | parkinsonsnewstoday.com | Andrea Lobo

VTX3232, an NLRP3 inhibitor being developed by Ventyx Biosciences as a treatment for Parkinson’s disease, was found to be safe and well tolerated after nearly one month of daily dosing in a clinical trial involving people with early-stage disease, according to the company. With these results, VTX3232 met the primary goal of the Phase 2a study (NCT06556173), which was conducted in Connecticut, Ventyx announced in a company press release.
Fabhalta raises hemoglobin, eliminates need for transfusion in PNH patients

5 days ago | pnhnews.com | Andrea Lobo

Six months of Fabhalta (iptacopan) raised hemoglobin levels, eliminated the need for blood transfusions, and eased fatigue in most adults with paroxysmal nocturnal hemoglobinuria (PNH) who switched from standard anti-C5 therapies.